Credits: Canva
The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.
It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.
The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.
In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.
TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."
Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.
While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.
Credit: @EmbaCubaUS/X
Scientists in Cuba have developed a novel vaccine against lung cancer that has shown the potential to improve survival rates among people living with the disease.
The vaccine, chemically known as racotumomab, has been developed in collaboration with scientists from Argentina. Vaxira has been approved in Cuba and Argentina for advanced non-small cell lung cancer (NSCLC).
It helps the immune system recognize and destroy lung cancer cells.
According to the Cuban Embassy in the US, the vaccine "works by mimicking a molecule found on cancer cells but almost entirely absent in healthy human tissue". It also targets tumors with remarkable precision and has very few side effects.
While advanced NSCLC has limited curative options and poor survival rates, clinical trials of Vaxira showed a significant improvement in survival.
Notably, "one-year survival among patients receiving the vaccine nearly doubled compared with the control group," the post said.
"Real-world data shows median survival of up to 24.5 months in maintenance therapy," it added.
Improved Survival And Minimal Side Effects
Importantly, the vaccine has demonstrated minimal side effects and is considered suitable for long-term use.
The embassy described the vaccine as affordable and accessible compared with many immunotherapies.
In 2025, Vaxira also received Cuba's National Technological Innovation Award.
The commercial rollout of Vaxira is being facilitated by the international public-private consortium ReComBio, linking Havana's Center of Molecular Immunology (CIM) with Argentina's Elea Laboratories.
Lung Cancer is one of the most common and serious types of cancer. It is also the leading cause of cancer-related deaths worldwide, with approximately 2.5 million new cases and 1.8 million deaths reported in 2022.
According to the American Cancer Society, lung cancer mainly occurs in older people. Most people diagnosed with lung cancer are 65 or older; a very small number of people diagnosed are younger than 45.
The average age of people when diagnosed is about 70.
It is also the leading cause of cancer death in the US, accounting for about 1 in 5 of all cancer deaths.
The two main types of lung cancers are:
Non-small-cell lung cancer (NSCLC): This is the most common form, making up about 80–85% of all cases. NSCLC includes three subtypes:
Small-cell lung cancer (SCLC): Less common than NSCLC, this type tends to grow and spread more quickly.
Lung cancer symptoms can mimic less serious conditions, which is why they’re often dismissed or misdiagnosed. If you experience the following symptoms persistently, don’t ignore them—regardless of your age or smoking history:
Credit: AI generated image
The International Space Station is conducting a very important study as Expedition 74 astronauts are researching how to manufacture large quantities of stem cells for treatment purposes on Earth. Research previously mostly worked on hardware to produce a large amount of stem cells, but now the InSPA-StemCellEX-H2 is trying to produce the cells for medical purposes.
This endeavor will rely on the process called “expansion”, which will use the stem cells from the human body and divide them. Though this is already possible on earth, the quality of created stem cells is far poorer than those from the human body, as it cannot create new cells in the blood, but the ones created in space will solve this problem, which will be crucial in the treatment of leukemia, as they need stem cells in the blood system post-chemotherapy.
Dr. Tobias Niederwieser, assistant research professor at BioServe Space Technologies within the University of Colorado Boulder, says, “The microgravity environment in space is much more suitable for keeping the stem cells in their high-quality state during expansion.” He added, “The result is really to benefit patients in hospitals here on Earth.”
Read Also: Pancreatic Cancer: What Is The Role Of Keratin 17 In Driving The Feared Disease?
Credit: AP
The White House has announced that US President Donald Trump is in “excellent health”. But doctors flag missing medical details.
Trump, 79, underwent an annual medical examination at the Walter Reed National Military Medical Center on May 26. Shortly after the test that lasted three hours, he shared that “everything checked out perfectly.”
Dr. Sean Barbabella, physician to the president, in a memorandum released late last week, said that “President Trump is demonstrating strong cardiac, pulmonary, neurological, and overall physical function.” He added that Trump is “fully fit to carry out all duties of the Commander-in-Chief and Head of State.”
However, doctors stated that the test results authorized by the President for public release contain notable gaps.
According to experts, the physical examination lacks detailed results from tests used to assess cardiovascular health.
Barbabella’s description of Trump’s cardiac health cites results from a coronary CT angiography, an echocardiogram, and an artificial-intelligence-enhanced electrocardiogram analysis.
Jonathan Reiner, Professor of Medicine and Surgery, Interventional Cardiologist, in a post on social media platform X, questioned the need for another coronary artery CT on Trump, as he was last scanned in October.
"We don’t typically scan patients 6 months later unless we are concerned about a finding on the initial scan. What prompted the repeat CT?" he said.
Further, to fully assess the president’s cardiac health, other doctors said they would want to see a calcium score, a description of any plaque in the arteries, and a CAD-RADS score to assess narrowing in the arteries, The Wall Street Journal reported.
“If I were creating a report to send to another physician, I would have mentioned a little bit more about the carotid ultrasound,” William Shutze, a Texas vascular surgeon, was quoted as saying. “What amount of plaque there is going to be—because almost all of us are going to have some buildup there.”
Also Read: President Donald Trump Remains In Excellent Health, Says White House
Further, Trump’s cholesterol numbers and medication regimen also attracted attention from physicians who reviewed the memorandum.
According to the report, his HDL (good cholesterol) level was 70 mg/dL, while his LDL (bad cholesterol) level was 53 mg/dL.
The report said Trump takes rosuvastatin and ezetimibe for cholesterol management.
“He’s got like the best cholesterol numbers you’ll see,” said Daniel Torrent, adding that it is unusual for medication alone to achieve such favorable values. “We don’t usually manage people to the point where they’re that good.”
“That report is almost too good to be true for somebody of his age,” Shutze said. “This seems to be a filtered narrative.”
Notably, neurological condition of Trump, the oldest elected as President of America, has remained a subject of serious discussion, with many doctors pointing out that he's suffering from dementia. But the test results revealed him to be in “normal mental status".
Cognitive function, assessed using the Montreal Cognitive Assessment (MoCA), was also within normal limits, with a score of 30 out of 30.
"Why was the president again given a MOCA dementia screening test? He’s had 3 in the recent past," Reiner asked, while also questioning Trump's "more frequent than the traditional yearly exam?"
Also read: ‘Sea Or See?’ Donald Trump's Remark Sparks Fresh Cognitive Health Speculation
“President Trump has publicly released more detailed information about his health than any other president in history—showing he is in excellent health,” White House communications director Steven Cheung said in a written statement.
He criticized outside physicians for speculating about a report for a patient not under their care, the WSJ said.
The White House added that “the absence of discussion regarding a specific medication, dosage, or historical medical condition should not be interpreted as a lack of monitoring or treatment”.
© 2024 Bennett, Coleman & Company Limited